Pediatric Oncology Branch Clinical Care and Education

儿科肿瘤学分支的临床主任负责监督NIH临床中心的儿科肿瘤学临床服务，并对临床研究员、执业护士和患者护理协调员承担预算和监督责任。NCI奖学金培训计划是与约翰霍普金斯医疗机构的联合培训计划。联合培训计划由研究生医学教育认证理事会（ACGME）认证。我们一起监督20名研究员的指导和培训。POB临床中心（CC）在atezolizumab治疗腺泡状软组织肉瘤（PI A）患者的研究中发挥了主导作用。Chen），招募了参与本研究的大多数儿科患者，这对FDA批准atezolizumab用于成人和2岁及以上的腺泡状垒球部肉瘤儿科患者至关重要。CC还领导发表了一项guadecitabine治疗SDH缺陷型GIST的研究（2023），以及一项研究者启动的ganitumab + dasatinib治疗横纹肌肉瘤患者的I期研究。

The Clinical Director of the Pediatric Oncology Branch oversees the pediatric oncology clinical service at the NIH Clinical Center and has budgetary and supervisory responsibility for the clinical fellows, nurse practitioners, and patient care coordinators. The NCI fellowship training program is a joint training program with Johns Hopkins Medical Institutions. The joint training program is accredited by the Accreditation Council for Graduate Medical Education (ACGME). Together we oversee the mentoring and training of 20 fellows. The POB Clinical Core (CC) played a lead role in the study of atezolizumab in patients with alveolar soft part sarcoma (PI A. Chen), enrolling the majority of pediatric patients who participated in this study which was critical to the FDA approval of atezolizumab for adults and pediatric patients age 2 years and older with alveolar softball part sarcoma. The CC also led the publication of a study of guadecitabine for the treatment of SDH-deficient GIST (2023) and an investigator initiated phase 1 study of ganitumab plus dasatinib for patients with rhabdomyosarcoma.